Diagnostic tests reported (number of tests)

Product tests sold (number of tests)

Total test volume (number of tests)

Number of sales team representatives (count of representatives)

c150983838bcab8163ff47816709835baf4e4b52ff2e2dbc8bf1dbbf6584a1f8

Testing Revenue

Product Revenue

Biopharma & Other Revenue

- Biopharma Revenue

- Contract Mfg & Testing

Total Revenue

5214c2bff15364f4260e643c96e407a950c0310e59a49fb59a447bba5e8d3e36

Net income (loss) [USD, thousands]

Depreciation and amortization [USD, thousands]

Loss on disposal of property, plant and equipment [USD, thousands]

Stock-based compensation [USD, thousands]

Deferred income taxes [USD, thousands]

Interest on end-of-term debt obligation [USD, thousands]

Noncash lease expense [USD, thousands]

Revaluation of acquisition-related contingent consideration [USD, thousands]

Impairment loss [USD, thousands]

Effect of foreign currency on operations [USD, thousands]

Net cash provided by operating activities [USD, thousands]

Purchase of short-term investments [USD, thousands]

Proceeds from sale of short-term investments [USD, thousands]

Proceeds from maturity of short-term investments [USD, thousands]

Acquisition of C2i, net of cash acquired [USD, thousands]

Purchases of property, plant and equipment [USD, thousands]

Net cash provided by (used in) investing activities [USD, thousands]

Payment of contingent consideration for acquisition [USD, thousands]

Payment of long-term debt [USD, thousands]

Payment of taxes on vested restricted stock units [USD, thousands]

Proceeds from the exercise of common stock options and employee stock purchases [USD, thousands]

Net cash provided by financing activities [USD, thousands]

Increase (decrease) in cash, cash equivalents and restricted cash [USD, thousands]

Effect of foreign currency on cash, cash equivalents and restricted cash [USD, thousands]

Net increase (decrease) in cash, cash equivalents and restricted cash [USD, thousands]

Purchases of property and equipment included in accounts payable and accrued liabilities [USD, thousands]

Cash paid for interest on debt [USD, thousands]

Cash paid for tax [USD, thousands]

Accounts receivable [USD, thousands]

Supplies and inventory [USD, thousands]

Prepaid expenses and other current assets [USD, thousands]

Other assets [USD, thousands]

Operating lease liability [USD, thousands]

Accounts payable [USD, thousands]

Accrued liabilities and deferred revenue [USD, thousands]

Cash, cash equivalents and restricted cash at beginning of year [USD, thousands]

Cash, cash equivalents and restricted cash at end of year [USD, thousands]

d6f66663b939335d55d8ce8e367738a24b2dce3ea27641a4dc73dc1e6b6665d2

Testing revenue (USD, thousands)

Product revenue (USD, thousands)

Biopharmaceutical and other revenue (USD, thousands)

Total revenue (USD, thousands)

Cost of testing revenue (USD, thousands)

Cost of product revenue (USD, thousands)

Cost of biopharmaceutical and other revenue (USD, thousands)

Intangible asset amortization - cost of revenue (USD, thousands)

Total cost of revenue (USD, thousands)

Gross profit (USD, thousands)

Research and development (USD, thousands)

Selling and marketing (USD, thousands)

General and administrative (USD, thousands)

Impairment of long-lived assets (USD, thousands)

Intangible asset amortization - operating expenses (USD, thousands)

Total operating expenses (USD, thousands)

Income (loss) from operations (USD, thousands)

Other income, net (USD, thousands)

Income (loss) before income taxes (USD, thousands)

Income tax provision (benefit) (USD, thousands)

Net income (loss) (USD, thousands)

Basic earnings (loss) per share (USD)

Diluted earnings (loss) per share (USD)

Shares used to compute basic earnings (loss) per common share (thousands)

Shares used to compute diluted earnings (loss) per common share (thousands)

4cb4d8de5bc6f43c15a5f91c28161db1b2b9225636c4ac02869680b6fc815102

Cash and Cash Equivalents (USD, thousands)

Short-Term Investments (USD, thousands)

Accounts Receivable (USD, thousands)

Supplies and Inventory (USD, thousands)

Prepaid Expenses and Other Current Assets (USD, thousands)

Total Current Assets (USD, thousands)

Property, Plant and Equipment, Net (USD, thousands)

Right-of-Use Assets, Operating Leases (USD, thousands)

Intangible Assets, Net (USD, thousands)

Goodwill (USD, thousands)

Restricted Cash (USD, thousands)

Other Assets (USD, thousands)

Total Assets (USD, thousands)

Accounts Payable (USD, thousands)

Accrued Liabilities (USD, thousands)

Current Portion of Deferred Revenue (USD, thousands)

Current Portion of Acquisition-Related Contingent Consideration (USD, thousands)

Current Portion of Operating Lease Liabilities (USD, thousands)

Current Portion of Other Liabilities (USD, thousands)

Total Current Liabilities (USD, thousands)

Deferred Tax Liability (USD, thousands)

Acquisition-Related Contingent Consideration, Net of Current Portion (USD, thousands)

Operating Lease Liabilities, Net of Current Portion (USD, thousands)

Other Liabilities (USD, thousands)

Total Liabilities (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

Accumulated Deficit (USD, thousands)

Accumulated Other Comprehensive Loss (USD, thousands)

Total Stockholders' Equity (USD, thousands)

Total Liabilities and Stockholders' Equity (USD, thousands)

8a060c3de0c6e1f7b2a42b6ca845353b0244a8373e426217785c777d419c2c9e

United States

International

b8a05a43d9d6eb7dfc2c747fb09d9606fd90cc89f24e4622ec2446c1f55913c5

Veracyte Inc (VCYT)

Financials